*This announcement contains forward-looking statements that involve risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

**Ocumension Therapeutics**
**歐康維視生物**
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock code: 1477)**

# ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024

The Board of Directors of the Company is pleased to announce the audited consolidated annual results of the Group for the year ended December 31, 2024, together with the comparative figures for the year ended December 31, 2023 as follows. These consolidated financial statements of the Group for the Reporting Period have been reviewed by the Audit Committee and audited by the Company's auditors, Messrs. Deloitte Touche Tohmatsu.

In this announcement, "we", "us" and "our" refer to the Company and where the context otherwise requires, the Group. Certain amounts and percentage figures included in this announcement have been subject to rounding adjustments, or have been rounded to one or two decimal places. Any discrepancies in any table, chart or elsewhere between totals and sums of amounts listed therein are due to rounding.

## BUSINESS HIGHLIGHTS

During the Reporting Period, our Company recorded revenue of RMB417.3 million, representing a year-on-year increase of 69.4%, with a comprehensive gross profit margin of approximately 53.9%. Our Core Product, Youshiying® (優施瑩®) (fluocinolone intravitreal implant) and key products, including Ou Qin (歐沁®) (sodium hyaluronate eye drops), Emadine® (埃美丁®) (emedastine eye drops), and Xalatan® (適利達®) (latanoprost eye drops), sustained rapid growth.

Our Core Product, Youshiying® (0.18mg fluocinolone intravitreal implant), was officially approved and included in the NRDL issued by the NHSA. Our innovative drug, ZERVIATE® (智維泰®) (0.24% cetirizine eye drops), was also approved for commercialization. We held a launch conference for ZERVIATE®, highlighting its unique dual mechanism of action in both anti-allergic and anti-inflammatory effects during the Reporting Period.

During the Reporting Period, the biologic license application (BLA) of OT-702 was accepted by the CDE in July 2024. In addition, OT-502 (dexamethasone implant) has also successfully achieved the expected primary efficacy endpoints of its phase III clinical trial and its NDA was accepted by the NMPA in September 2024.

During the Reporting Period, we officially commenced the production of commercial batches. The commercial production of four products was launched in an orderly manner, which will offer a quality, stable and efficient product supply for our Company's commercial pipeline in the future.

## FINANCIAL HIGHLIGHTS

The revenue of our Group increased by 69.4% from RMB246.4 million for the year ended December 31, 2023 to RMB417.3 million for the year ended December 31, 2024, primarily led by (i) a significant increase in the revenue generated from the sales of our ophthalmic products, including Youshiying®, Xalatan® and Xalacom® (適利加®); and (ii) the strategic cooperation with Alcon, which generated synergy and contributed to the increase in our revenue.

We recorded adjusted net loss of RMB183.6 million (non-IFRS adjustment) for the year ended December 31, 2024, representing a significant decrease of RMB59.6 million from RMB243.2 million for the year ended December 31, 2023. This narrowed adjusted net loss mainly attributed to the significant increase in our revenue and gross profit generated from the sales of our ophthalmic products.

As of December 31, 2024, we had approximately RMB769.2 million in bank balances and cash.

# CORPORATE PROFILE

## Overview

We are a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercializing first- or best-in-class ophthalmic therapies. Our vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. We believe our ophthalmic pharmaceutical platform, which enjoys a clear first-mover advantage, will enable us to obtain and maintain our leadership position in the field of ophthalmology in China.

To date, the Company has established a complete ophthalmic drug pipeline with 34 front- and back-of-the-eye drug assets, among which 21 products are at the commercialization stage, three products are in phase III clinical trial and two innovative drugs have reached the registration stage for commercialization. Our Core Product, Youshiying® (0.18mg fluocinolone intravitreal implant), was officially approved and included in the NRDL issued by the NHSA. Our innovative drug, ZERVIATE® (0.24% cetirizine eye drops), was also approved for commercialization. The following table summarizes our product portfolio and the status of each drug asset as of December 31, 2024:

| Pipeline | MoA/Molecule | Indications | Rights | Partners | Pre | Phase I/II | PhIII/RWE | Launch/NDA |
|---|---|---|---|---|---|---|---|---|
| **Uveitis, fundus diseases** | | | | | | | | |
| OT-401 **Yutiq**® | Fluocinolone intravitreal implant | Chronic NIU-PS | Greater China, Korea, +11 SEA countries | EyePoint Pharmaceuticals | | | | |
| OT-702 **Boyoujing (博優景®)** | Aflibercept intravitreous injection | wAMD, DME | Chinese Mainland | Boan Biotech 博安生物 | | | | * |
| OT-402 **Visudyne**® | Verteporfin | wAMD with choroidal neovascularisation | Chinese Mainland | CHEPLAPHARM | | | | ** |
| OT-703 **Ocusingen**® | Fluocinolone intravitreal implant | DME | Greater China, Korea, +11 SEA countries | ani Pharmaceuticals, Inc. | | | | |
| OT-701 | Ranibizumab | wAMD | Greater China | SENJU 参天製薬 | | | | |
| OT-1601 | Stem Cell | Retinitis pigmentosa, dAMD | Greater China | SanBio | | | | |
| OT-1602 | Stem Cell | Optic neuritis | Greater China | SanBio | | | | |
| **Refractive correction** | | | | | | | | |
| OT-101 | Low-concentration atropine eye drops | Myopia | Global | Self-developed | | | | |
| OT-802 | Pilocarpine Hydrochloride | Presbyopia | Global | Self-developed | | | | |
| **DED** | | | | | | | | |
| OT-204 Ou Qin (歐沁) | HA | | Chinese Mainland | 汇恩兰德 HUONLAND | | | | |
| OT-208 **Bion tears**® | 0.4ml Dextran 70/Hydromellose | | Chinese Mainland | Alcon 爱尔康 | | | | |
| OT-209 **Tears Naturale Free**® | 15ml Dextran 70/Hydromellose | | Chinese Mainland | Alcon 爱尔康 | | | | |
| OT-210 **Tears Naturales Forte**® | Hypromellose 2910, Dextran 70 and Glycerol | | Chinese Mainland | Alcon 爱尔康 | | | | |
| OT-212 **Systane Ultra**® | polyethylene glycol 400/propylene glycol | | Chinese Mainland | Alcon 爱尔康 | | | | |
| OT-202 | Spleen tyrosine kinase inhibitor | | Global | Self-developed | | | | |
| OT-503 NCX 4251 | Fluticasone Propionate Nanocrystals | | Greater China | nicox visible science | | | | |
| **Glaucoma** | | | | | | | | |
| OT-305 **Betoptic S** | Betaxolol hydrochloride | | Chinese Mainland | NOVARTIS | | | | |
| OT-306 **Xalatan**® | Latanoprost | | Chinese Mainland | VIATRIS | | | | |
| OT-307 **Xalacom**® | Llatanoprost and timolol maleate | | Chinese Mainland | VIATRIS | | | | |
| OT-303 Oudesai (歐德賽®) | Brimonidine tartrate | | Chinese Mainland | 汇恩兰德 HUONLAND | | | | |
| OT-301 NCX 470 | Bimatoprost grenod | | Greater China, Korea, 12 SEA countries | nicox visible science | | | | |
| **Conjunctivitis** | | | | | | | | |
| OT-1001 **Zerviate**® | Cetirizine hydrochloride | Allergic conjunctivitis | Greater China, Korea, +11 SEA countries | nicox visible science | | | | |
| OT-1004 **Emadine**® | Emedastine difumarate | Allergic conjunctivitis | Chinese Mainland | NOVARTIS | | | | |
| OT-1005 **Azep**® | Azelastine hydrochloride | Allergic conjunctivitis | Chinese Mainland | VIATRIS | | | | |
| OT-606 **Natacyn**® | Natamycin | Fungus disease | Greater China | HARROW | | | | |
| OT-601 Kangwenjuan (康文消®) | Moxifloxacin | Bacterial conjunctivitis | Global | Self-developed | | | | |
| OT-604 Kangxiaoqing (康小清®) | Levofloxacin | Bacterial conjunctivitis | Global | Self-developed | | | | |
| **Surgery** | | | | | | | | |
| OT-502 **Dexycu**® | Dexamethasone (intraocular suspension) | Oostoperative ocular inflammation | Greater China, Korea, +11 SEA countries | EyePoint Pharmaceuticals | | | | * |
| OT-1403 **Cyclogyl**® | Cyclopentolate hydrochloride | Paralysis of ciliary muscle, pupil dilation | Chinese Mainland | Alcon 爱尔康 | | | | |
| OT-1404 **Alcaine**® | Proparacaine hydrochloride | Topical ocular anesthesia | Chinese Mainland | Alcon 爱尔康 | | | | |
| OT-1702 **Fluorescite**® | Fluorescein sodium | Used in fluorescein angiography | Chinese Mainland | Alcon 爱尔康 | | | | |
| OT-1402 Ougaolin (歐高林®) | Oxybuprocaine hydrochloride | Surface anesthesia of the eye | Global | Self-developed | | | | |
| OT-601-C | Moxifloxacin Dexamethasone Suspension | Treatment of ocular inflammation | Global | Self-developed | | | | |

Partnership Self-developed

Note: **Marketing application has been submitted; ** have commercial rights.*

## MANAGEMENT DISCUSSION AND ANALYSIS

### Business Review

During the Reporting Period, we have been making significant progress with respect to our pipeline products and business operations, including the following milestones and achievements:

#### *Overall Financial Performance*

During the Reporting Period, our Company recorded revenue of RMB417.3 million, representing a year-on-year increase of 69.4%, with a comprehensive gross profit margin of approximately 53.9%. Our Core Product, Youshiying® (fluocinolone intravitreal implant) and key products, including Ou Qin (sodium hyaluronate eye drops), Emadine® (emedastine eye drops), and Xalatan® (latanoprost eye drops), sustained rapid growth. In addition, the introduction of various eye drops products from Alcon Group contributed incremental business to our Group, further enriching our product portfolio, expanding our market presence, and increasing our market share. Our R&D expenses were RMB113.9 million, and we continued steadily advancing the R&D of our pipeline candidates. Notably, ZERVIATE® (0.24% cetirizine eye drops), a new drug for the treatment of allergic conjunctivitis, has been approved for marketing in September 2024, and two innovative products have entered the registration stage for commercialization. Our Company recorded an adjusted net loss of RMB183.6 million (non-IFRS adjustment) for the Reporting Period, representing a year-on-year decrease of 24.5%, primarily attributable to the significant increase in our revenue and gross profit generated from the sales of our ophthalmic products.

#### *Research and Development Performance*

During the Reporting Period, several of our clinical R&D projects advanced to the registration stage for commercialization, showcasing our strong clinical R&D capabilities and injecting new momentum into our commercialization efforts. Approved by the NMPA for marketing, ZERVIATE® (0.24% cetirizine eye drops) is currently the only anti-allergic ophthalmic drug approved by the FDA for use in patients aged two years and older. In February 2025, the Company held a launch conference for ZERVIATE®, highlighting its unique dual mechanism of action in both anti-allergic and anti-inflammatory effects. The Company has completed the phase III clinical trial for OT-702 (Boyoujing (博優景®), aflibercept intravitreous injection) in China with positive results during the Reporting Period, and the biologic license application (BLA) of OT-702 was accepted by the CDE in July 2024. In addition, OT-502 (dexamethasone implant) has also successfully achieved the expected primary efficacy endpoints of its phase III clinical trial and its NDA was accepted by the NMPA in September 2024. Moreover, the phase II clinical trial of OT-202 (tyrosine kinase inhibitor), a first-in-class new drug self-developed by our Company for the treatment of dry eye, has been successfully completed with its primary clinical endpoint achieved.

To date, the Company has three products in phase III clinical trial and two products in the registration stage for commercialization, comprehensively covering both front- and back-of-the-eye diseases. With a well-rounded and strategically balanced product portfolio thoughtfully designed across various stages of development, the Company maintains its position as a leading innovative ophthalmic pharmaceutical company in China. The Company stands as one of the leading domestic ophthalmic pharmaceutical companies with the highest number of drugs in phase III clinical trials and registration stage. Moreover, the Company leads the country in the number of ophthalmic drugs that have passed or are deemed to have passed the consistency evaluation, delivering robust pipeline support through continuous R&D output.

***Research and Development Progress of Our Key Drug Candidates***

- OT-101 (0.01% atropine sulfate eye drops)

  During the Reporting Period, we continued to advance the phase III clinical trial of OT-101.

  We expect to complete the phase III clinical trial of OT-101 in 2026.

- OT-202 (tyrosine kinase inhibitor)

  In March 2024, OT-202, a first-in-class new drug self-developed by the Company for the treatment of dry eye, has successfully completed the unblinding with all related data collected, which marks the achievement of primary clinical endpoint of phase II clinical trial (i.e., the group that received the treatment with the drug exhibited greater improvement in corneal staining scores from baseline compared to the placebo group by day 56). The drug has also demonstrated positive results in safety and efficacy.

  We expect to launch the phase III clinical trial of OT-202 in 2025.

- OT-702 (Boyoujing (博優景®), aflibercept intravitreous injection)

  In April 2024, the phase III clinical trial (clinical efficacy and safety comparison trial) of OT-702, an anti-VEGF drug, was successfully completed in China. The results of this phase III clinical trial demonstrated clinically significant improvement in the eye's best corrected visual acuity (BCVA) under study at weeks 4, 8, 12, 16, 20 and 24 compared with the baseline (by using the early treatment of diabetic retinopathy study (ETDRS) visual acuity chart) for the patients in both trial group and original reference drug group. The therapeutic effectiveness of OT-702 and the original reference drug is highly comparable, where the onset of action of both is rapid and lasting, signifying the fulfillment of all clinical trial endpoints.

  In July 2024, the biological license application (BLA) of OT-702 was accepted by the CDE. OT-702 is expected to be approved for commercialization in 2025.

- OT-502 (DEXYCU®, dexamethasone implant)

  In April 2024, OT-502, a new drug for the treatment of postoperative inflammation indication, successfully achieved the expected primary efficacy endpoints of its phase III clinical trial. The phase III clinical trial of OT-502 is designed to be a randomized, double-masked, placebo-controlled, parallel-group, multi-center clinical and pharmacokinetic study to evaluate the efficacy and safety of 9% dexamethasone implant in the treatment of post-cataract surgery inflammation, and the expected primary efficacy endpoints of the phase III clinical trial of OT-502 showed that the treatment group receiving the dexamethasone implant exhibited a notably higher proportion of subjects with anterior chamber cells clearing (ACC grade 0) compared to the placebo group by day 8, demonstrating the safety and efficacy of the product in managing post-cataract inflammation. The NDA of OT-502 has been accepted by the NMPA in September 2024.

  We expect OT-502 to be approved for commercialization this year.

- OT-301 (NCX 470)

  In December 2024, OT-301 (NCX 470), a first-in-class, nitric oxide (NO)-donating prostaglandin analog, completed the enrollment of over 140 patients for its second phase III clinical trial (the "**Denali trial**") in China. The Denali trial is a three-month phase III multi-regional clinical trial evaluating the safety and efficacy of OT-301 ophthalmic solution, 0.1%, versus the current standard of care, latanoprost ophthalmic solution, 0.005%, for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  We expect to complete the phase III clinical trial of OT-301 this year.

**WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND/OR MARKET OUR CORE PRODUCT AND/OR DRUG CANDIDATES SUCCESSFULLY.**

***Commercialization Performance***

During the Reporting Period, the Company actively expanded its hospital coverage and accelerated the admission of its products into hospitals. Following its inclusion in the updated NRDL, the sales of Youshiying® achieved a rapid breakthrough. Meanwhile, the Company further explored the commercial potential of products such as Emadine®, Xalatan®, and Ou Qin, driving rapid growth in the Company's revenue. The Company recorded a total revenue of RMB417.3 million from its commercialized products, representing a year-on-year increase of 69.4%. The Company has expanded its coverage to 20,466 hospitals nationwide, including 2,765 Grade III hospitals. With a commercial team of over 270 members, the Company has established full national business network coverage.

In August 2024, the Group entered into the Alcon Transaction with Alcon Group, under which Ocumension obtained the relevant rights and interest pertaining to eight products in China from Alcon Group, including seven mature products already commercialized in the market and one innovative drug currently in clinical development. According to the transaction documents of the Alcon Transaction, the Group has acquired (a) all of the rights, titles and interests in and to the Transferred Products, namely Tears Naturale® Forte (新淚然®), Tears Naturale® II (淚然®II), Bion® Tears (倍然®), Alcaine® (愛爾凱因®), Fluorescite® (歷設得®), and Cyclogyl® (賽飛傑®), to manufacture and commercialize these products in the PRC, (b) the right to commercialize the Commercial Product, namely Systane® Ultra (思然®) in the PRC; and (c) the rights to develop, manufacture and commercialize the Pipeline Product, a novel topical drug candidate for dry eye in the PRC. As consideration for the Alcon Transaction, the Company issued 139,159,664 Shares to Alcon Pharma on October 16, 2024 ("**Alcon Consideration Issue**"), representing 16.99% of the total issued Shares of the Company (excluding the treasury Shares) on the date of Alcon Consideration Issue. As such, Alcon Pharma became a substantial Shareholder of the Company. Under the terms of the transaction documents of the Alcon Transaction, each party has granted the other a right of first negotiation for future products. The acquisition and in-licensing of the seven

mature products (namely the Transferred Products and Commercial Product) and the Pipeline Product is expected to further strengthen Ocumension's leading position in the ophthalmology market in China. Through the Alcon Transaction, Ocumension aims to offer more comprehensive and advanced treatment solutions, better meet patient needs, and further expand its market share.

***Manufacturing Performance***

During the Reporting Period, the Company officially commenced the production of commercial batches. Leveraging advanced manufacturing techniques, efficient supply chain management and control, and a commitment to striving for perfection constantly, the eye-drop products made by Ocumension will provide the vast number of ophthalmic patients with more reliable high-quality ophthalmic drugs. The commercial production of four type of products was launched in an orderly manner, which will offer a quality, stable and efficient product supply for the Company's commercial pipeline in the future. We have completed the commercial production for a total of 11 batches of products during the Reporting Period. Three batches of process validation of production localization of Youshiying® have been carried out and subsequent applications will be advanced as planned.

**Future Development and Outlook**

With steady development in 2024, Ocumension made remarkable achievements in the ophthalmic pharmaceutical industry. We not only successfully marketed our Core Product Youshiying®, but also broadened our product pipeline, built a high-quality production base and achieved remarkable results in product promotion. Looking forward to the year 2025, guided by the slogan of "*Virtus et Lumen*", we will commit to the following goals:

- ***Speeding up the R&D and commercialization of new products***

  In terms of R&D of new products, we will continue increasing inputs to ensure that at least one NDA will be approved this year, upholding our trend of continuously launching new products. Our goal is to regularly diversify our product portfolio to better address the patient and market needs.

- ***Optimizing production and supply chain management***

  In 2025, we will focus on commercialized mass production at our Suzhou manufacturing site to ensure the stability of our supply and the quality of our products. We will also improve production efficiency and reduce costs by optimizing production processes and supply chain management.

- ***Promoting our Core Product Youshiying®***

  We are proud of our successful marketing of Youshiying®. Looking forward to 2025, we will intensify our promotional efforts to expand its reach, benefit more patients, and enhance market penetration, thereby reinforcing our leadership in the field of ophthalmic treatment.

- ***Strengthening the marketing and promotion of other drugs***

  We will enhance our efforts in the marketing and promotion of other drugs, including Xalatan®, Xalacom®, Betoptic® S (貝特舒®), Emadine® and Azep® (愛賽平®), to strengthen our leading position in the treatment of uveitis, anti-allergy and glaucoma market segments and drive the continued growth in our revenue.

- ***Further nurturing and advancing our corporate culture***

  Corporate culture is the cornerstone supporting our Company's development. In 2025, we will continue nurturing and advancing our corporate culture, fostering an environment that exemplifies the specific merits of Ocumension to ensure the sustainable development and growth of our Company as we move into the next phase.

- ***Expanding our international horizons***

  With the implementation of our globalization strategy, we will actively expand into the international market and explore cooperation opportunities with overseas partners so that we may bring our quality products to patients around the world. Particularly, the international footprint is expected to be achieved through the out-licensing of our innovative products. We believe that this international expansion will be a crucial step in realizing our vision of becoming an industrial leader in ophthalmic pharmaceuticals.

- ***Continuous innovation and leading technology***

  Innovation plays a key role in our Company's developmental momentum. We will continue investing in R&D to sustain our technological lead, and continue to explore new treatments and therapeutic approaches with the aim of providing patients with more effective and safer treatment regimes.

- ***Expansion of online OTC channels***

  Recognizing the growing importance of online sales channels, we will also focus on expanding our presence in the online OTC market. By enhancing our online OTC channels, we aim to provide a more convenient and efficient purchasing experience for our customers, thereby further increasing our market reach and customer base.

Going forward, Ocumension will continue to strive for excellence. Through a patient-centered and innovation-driven approach, we endeavor to become a leader in the field of ophthalmology. We believe that through our constant efforts, we can provide more comprehensive solutions to ophthalmic patients, improve the quality of their lives, and create sustainable growth in value for our Shareholders and investors.

## Financial Review

### *Revenue*

The revenue of our Group increased from RMB246.4 million for the year ended December 31, 2023 to RMB417.3 million for the year ended December 31, 2024, mainly attributed to (a) a significant increase of 87.8% in the revenue generated from the sales of our ophthalmic products, including (i) Youshiying® which was admitted into the updated NRDL in December 2023, (ii) Xalatan® and Xalacom®, and (iii) the products acquired and in-licensed from Alcon Group following the Alcon Transaction; (b) a notable increase of RMB9.8 million in the revenue generated from the CDMO services (as defined below), largely driven by a growing number of orders from business partners seeking CDMO services on ophthalmic products; and (c) a growth of RMB4.1 million in the sales-based royalty income; partially offset by a decrease in the revenue generated from the pharmaceutical products promotion services. This decrease was primarily due to a change in revenue recognition, as the relevant revenue was recorded as revenue from sales of ophthalmic products instead of revenue from pharmaceutical products promotion services during the Reporting Period, which was driven by a shift in the change of business model of Xalatan® and Xalacom®. The following table sets forth the components of the revenue for the years indicated:

| | For the year ended December 31, | |
|---|---|---|
| | **2024** | 2023 |
| | ***RMB'000*** | *RMB'000* |
| Sales of ophthalmic products | **384,345** | 204,695 |
| Pharmaceutical products promotion services | **15,706** | 38,347 |
| Sales-based royalty income | **7,175** | 3,054 |
| Contract development and manufacturing ("**CDMO**") services | **10,081** | 271 |
| **Total Revenue** | **417,307** | 246,367 |

For the sale of ophthalmic products, revenue is recognized when control of the goods is transferred, being when the goods have been delivered to the customer's specific location, i.e., when the products are delivered and titles are passed to customers upon receipt by customers. For pharmaceutical products promotion services, revenue is recognized at a point in time when we satisfy the obligation to arrange for sales and/or delivery of pharmaceutical products pursuant to the service contracts. The sales-based royalty income is based on the profit margin of each sale and is recognized at a point of time upon the customer completes its sales. The CDMO service revenue is recognized at the point in time when the deliverables are delivered to our customers.

### *Cost of Sales*

Our cost of sales mainly consists of purchase price of goods and amortization of license rights. Our cost of sales increased from RMB102.0 million for the year ended December 31, 2023 to RMB192.2 million for the year ended December 31, 2024. The increase was mainly due to (i) the increased cost in relation to our sales of ophthalmic products and amortization of license rights, which was generally in line with our revenue growth; and (ii) the change of business model of Xalatan® and Xalacom® from providing promotion services to product sales.

### *Gross Profit*

The gross profit of our Group increased by 55.9% from RMB144.4 million for the year ended December 31, 2023 to RMB225.1 million for the year ended December 31, 2024. The increase in the gross profit was generally in line with our revenue growth.

### *Other Income*

Our other income mainly consists of (i) bank interest income arising from our bank deposit, (ii) the compensation from Alcon, and (iii) government grant income. For the year ended December 31, 2024, our other income was RMB46.7 million, representing an increase of approximately RMB23.5 million from RMB23.2 million for the year ended December 31, 2023, primarily due to the compensation from Alcon Group for the potential excess stock held by its original distributor's at the time of closing of the Alcon Transaction.

### *Other Gains and Losses*

We incurred other gains of RMB1.4 million for the year ended December 31, 2024, as compared to the other gains of RMB5.4 million recorded for the year ended December 31, 2023, primarily due to (i) the absence of a reversal of impairment loss on long-lived assets in 2024, compared to a reversal amount of RMB3.2 million in 2023; (ii) a reduction in changes in the fair value of other financial assets, with recorded gains of only RMB0.5 million in 2024, compared to RMB1.2 million in 2023; and (iii) loss of RMB0.6 million incurred from the subscription of shares of Nicox. These decreases were partially offset by a RMB0.8 million increase in net foreign exchange gains during the year ended December 31, 2024.

### *Selling and Marketing Expenses*

Our selling and marketing expenses mainly consist of (i) salary and benefits expenses for our commercialization team; (ii) share-based payments for our commercialization team; and (iii) marketing and promotion expenses. For the year ended December 31, 2024, our selling and marketing expenses were RMB227.7 million, representing a slight increase of RMB1.4 million from RMB226.3 million for the year ended December 31, 2023.

The following table sets forth the components of our selling and marketing expenses for the years indicated:

| | For the year ended December 31, | |
|---|---|---|
| | **2024** | 2023 |
| | ***RMB'000*** | *RMB'000* |
| Salary and benefits | **116,164** | 91,133 |
| Share-based payments | **29,758** | 52,257 |
| Marketing and promotion | **55,628** | 56,803 |
| Others | **26,148** | 26,060 |
| **Total selling and marketing expenses** | **227,698** | 226,253 |

***R&D Expenses***

During the Reporting Period, we recorded R&D expenses of RMB113.9 million, representing a decrease of 7.9% from RMB123.8 million for the year ended December 31, 2023. Such decrease was primarily due to (i) a decrease in third-party contracting costs, as we successfully completed the phase II clinical trial of a drug candidate and several in-house R&D projects during the Reporting Period; and (ii) a decrease in share-based payments for R&D staff during the Reporting Period as compared to last year.

The following table sets forth the components of our R&D expenses for the years indicated:

| | For the year ended December 31, | |
|---|---|---|
| | **2024** | 2023 |
| | ***RMB'000*** | *RMB'000* |
| Third-party contracting costs | **38,522** | 43,493 |
| Staff costs | **52,660** | 62,656 |
| Depreciation and amortization | **10,253** | 9,002 |
| Others | **12,500** | 8,617 |
| **Total R&D expenses** | **113,935** | 123,768 |

### *Administrative Expenses*

Our administrative expenses consist of (i) salaries and other expenses such as benefits, travel and share-based payments; (ii) professional service fee; (iii) depreciation and amortization of the property for the purpose of administrative use and right-of-use assets; and (iv) rental and related expenses.

For the year ended December 31, 2024, our administrative expenses were RMB189.2 million, representing a slight decrease of RMB6.9 million from RMB196.1 million for the year ended December 31, 2023, which was primarily due to a decrease in expenses related to share-based payments for administrative staff, partially offset by an increase in staff cost and professional fee in 2024 as compared to 2023.

### *Income Tax Expenses*

Our income tax expense mainly represents the profit tax in relation to the revenue incurred in markets inside and outside the PRC. Our income tax expense for the year ended December 31, 2024 was RMB1.0 million, increasing from RMB0.3 million for the year ended December 31, 2023, mainly due to higher profits from the wholly-owned subsidiaries of our Company.

### *Loss for the Year*

As a result of the above factors, for the year ended December 31, 2024, our loss was RMB268.3 million, representing a decrease of RMB111.5 million from RMB379.8 million for the year ended December 31, 2023, mainly attributable to an increase of RMB80.7 million in gross profit and a growth of RMB23.5 million in other income.

### *Non-IFRS Measures*

To supplement our consolidated financial statements which are presented in accordance with IFRS, we also use adjusted net loss for the year, a non-IFRS measure to present our operating performance. Adjusted net loss for the year, as an additional financial measure, is not required by, or presented in accordance with IFRS. We believe that such non-IFRS measure facilitates comparisons of our operating performance from year to year by eliminating impacts of non-cash items that our management considers to be not indicative of our operating performance and provides useful information to Shareholders and investors to evaluate our operating results in the same manner as our management does. However, our presentation of the adjusted net loss for the year may not be comparable to similarly titled measures presented by other companies. The use

of such non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation, or as substitute for analysis of, our results of operations or financial position as reported under IFRS. We define adjusted net loss for the year as loss for the year adjusted by adding back share-based payments and impairment loss reversed on long-lived assets. The following table reconciles our non-IFRS adjusted net loss for the year with our loss for the year:

| | For the year ended December 31, | |
|---|---|---|
| | **2024** | 2023 |
| | ***RMB'000*** | *RMB'000* |
| Loss for the year | **(268,274)** | (379,787) |
| *Add:* | | |
| Impairment loss reversed on long-lived assets | **–** | (3,179) |
| Share-based payments | **84,632** | 139,729 |
| **Non-IFRS adjusted net loss for the year** | **(183,642)** | (243,237) |

***Selected Data from Consolidated Statement of Financial Position***

| | As of December 31, | |
|---|---|---|
| | **2024** | 2023 |
| | ***RMB'000*** | *RMB'000* |
| Total current assets | **978,795** | 1,205,634 |
| Total non-current assets | **2,995,009** | 2,065,365 |
| **Total assets** | **3,973,804** | 3,270,999 |
| Total current liabilities | **155,001** | 315,284 |
| Total non-current liabilities | **45,186** | 35,747 |
| **Total liabilities** | **200,187** | 351,031 |
| **Net assets** | **3,773,617** | 2,919,968 |

***Trade Receivables***

We allow an average credit period of 30 to 90 days to our trade customers, and the credit terms of certain trade customers are based on the timing of their actual sales.

A majority of the trade receivables aged less than one year.

The increase in our trade receivables as of December 31, 2024 is generally in line with the growth of our revenue.

***Trade Payables***

A majority of the trade payables aged less than one year.

***Working Capital and Source of Capital***

Our primary uses of cash related to (i) expenses and costs for our daily operation and sales and marketing activities; (ii) R&D expenses in relation to the clinical trials for our drugs and/or drug candidates; and (iii) payments in relation to the construction project and production equipment at our Suzhou manufacturing site, as well as operational costs and fees incurred for the on-site trial production. During the Reporting Period, we primarily funded our working capital needs through equity financing and cash generated from (i) the sales of Youshiying®, Ou Qin, brimonidine tartrate eye drops, Emadine®, Xalatan®, Xalacom®, Kangwenjuan®, the Transferred Products and the Commercial Product; (ii) the pharmaceutical products promotion services; and (iii) the CDMO services. We monitor and maintain a level of cash and cash equivalents deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flows. As of December 31, 2024, our cash and cash equivalents amounted to RMB729.2 million (December 31, 2023: RMB842.8 million). Currently, we follow a set of funding and treasury policies to manage our capital resources and mitigate potential risks involved.

***Borrowings***

As of December 31, 2024, we recorded a loan of RMB16.5 million (December 31, 2023: RMB120.0 million). During the Reporting Period, our Group entered into loan agreements with banks with interest rates being the one-year's loan prime rate minus 0.35% (2023:3.0%~3.1%).

***Capital Commitment***

As of December 31, 2024, we have a capital commitment of RMB5.0 million for the contracts in relation to acquisition of property, plant and equipment (December 31, 2023: RMB6.4 million).

***Contingent Liabilities***

As of December 31, 2024, we did not have any material contingent liabilities, guarantees or any litigation against us (December 31, 2023: nil).

***Pledge of Assets***

As of December 31, 2024, we did not have any pledged assets (December 31, 2023: RMB4.3 million).

***Gearing Ratio***

Gearing ratio is calculated using interest-bearing borrowings less cash and cash equivalents and term deposits with initial term of over three months, divided by total equity and multiplied by 100%. As of December 31, 2024, we were in a net cash position and thus, gearing ratio is not applicable.

***Material Investments, Acquisitions and Disposals***

During the Reporting Period, the Group disposed of a total of 1,910,500 EyePoint Shares by way of block trade, at an aggregate consideration of approximately US$37,159,000 (equivalent to approximately HK$290,583,000) (exclusive of transaction costs), which was determined with reference to the then market price of EyePoint Shares based on arm's length negotiations between the parties and has been fully settled in cash. For details of the aforesaid disposal, please refer to the Company's announcement dated January 17, 2024. Upon the completion of the aforesaid disposal, we directly hold 100,221 EyePoint Shares, representing approximately 0.21% of the total issued and outstanding EyePoint Shares based on publicly available information as of the date of the aforesaid announcement.

As of December 31, 2024, the carrying amount of our investment in EyePoint as equity instruments at FVTOCI was approximately RMB5.4 million (December 31, 2023: RMB329.1 million). Accordingly, the fair value of such investment compared to our total assets as of December 31, 2024 was approximately 0.14%. During the Reporting Period, we have not received any dividend from such investment.

Additionally, our Group and Alcon entered into the Alcon Transaction, details of which are set out in the Company's announcement dated August 12, 2024 and the circular dated September 30, 2024. Upon the completion of the Alcon Consideration Issue, Alcon Pharma became our substantial Shareholder, holding 139,159,664 Shares, representing 16.99% of the total issued Shares of the Company (excluding the treasury Shares) on the date of Alcon Consideration Issue.

Save as disclosed above, the Company did not have any other material investments, acquisitions or disposals of subsidiaries, associates and joint ventures during the year ended December 31, 2024.

***Future Plans for Material Investments or Capital Assets***

As of the date of this announcement, we planned to continue investing in the construction of our Suzhou manufacturing site to enhance the manufacturing capacity to satisfy our long-term development strategies.

Saved as disclosed above, we did not have any concrete future plans for material capital expenditure, investments or capital assets as of the date of this announcement. We will make further announcements in accordance with the Listing Rules, where applicable, if any investments and acquisition opportunities materialize.

***Foreign Exchange***

Foreign currency risk refers to the risk of loss resulting from changes in foreign currency exchange rates. Certain of our bank balances and cash, trade and other receivables and trade and other payables are denominated in foreign currencies and are exposed to foreign currency risk. Our Group currently implements foreign currency hedging measures under our funding and treasury policies. In addition, we will continue to manage the foreign exchange risk by closely monitoring our foreign exchange exposure and will consider implementing more detailed measures as needed to hedge significant foreign currency exposure thus to prevent significant net foreign exchange losses in the future.

***Employees and Remuneration***

As of December 31, 2024, we had a total of 489 employees (December 31, 2023: 444). For year ended December 31, 2024, the total remuneration cost incurred, including the share-based payments, was RMB318.2 million (December 31, 2023: RMB314.6 million). The following table sets forth a breakdown of our employees by function as of December 31, 2024:

| **Function** | **Number** | **% of total** |
|---|---|---|
| Commercial | 271 | 55.4% |
| R&D | 57 | 11.7% |
| Manufacturing | 124 | 25.4% |
| Management and administrative | 37 | 7.6% |
| **Total** | **489** | **100%** |

We provide formal and comprehensive company-level and department-level training to our new employees, followed by on-the-job training. We also provide training and development programs to our employees from time to time to ensure their awareness and compliance with our various policies and procedures. Some of the training is conducted jointly by departments serving different functions but working with or supporting each other in our day-to-day operations.

The remuneration of the employees of our Group comprises salaries, bonuses, employees' provident fund, share-based payments, social security contributions and other welfare payments which is determined by their responsibilities, qualifications, positions and seniority. We regularly review and determine the remuneration and compensation package of the employees by reference to, among other things, their performance, qualifications, respective responsibilities and market levels of salaries paid by comparable companies. In accordance with applicable laws and regulations, we made contributions to social security insurance funds (including pension plans, medical insurance, work-related injury insurance, unemployment insurance and maternity insurance) and housing funds for our employees.

We have also adopted the ESOP, the RSU Scheme, the 2021 Share Option Scheme, the 2021 Share Award Scheme and the 2024 Share Award Scheme to provide incentives for our employees.

## CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE YEAR ENDED DECEMBER 31, 2024

| | *NOTES* | **2024** ***RMB'000*** | 2023 *RMB'000* |
|---|---|---|---|
| Revenue | *3* | **417,307** | 246,367 |
| Cost of sales | | **(192,242)** | (102,002) |
| Gross profit | | **225,065** | 144,365 |
| Other income | *4* | **46,738** | 23,203 |
| Other gains and losses | *5* | **1,430** | 5,430 |
| Impairment losses under expected credit loss ("ECL") model, net of reversal | | **(651)** | (349) |
| Selling and marketing expenses | | **(227,698)** | (226,253) |
| Research and development expenses | | **(113,935)** | (123,768) |
| Administrative expenses | | **(189,212)** | (196,142) |
| Other expenses | | **(6,831)** | (4,641) |
| Finance costs | | **(2,163)** | (1,325) |
| Loss before tax | | **(267,257)** | (379,480) |
| Income tax expense | *6* | **(1,017)** | (307) |
| Loss for the year | | **(268,274)** | (379,787) |
| **Other comprehensive (expense) income:** | | | |
| *Item that will not be reclassified to profit or loss:* | | | |
| Fair value (loss) gain on investments in equity instruments at fair value through other comprehensive income ("FVTOCI") | | **(47,450)** | 407,254 |
| | | **(47,450)** | 407,254 |
| **Total comprehensive (expense) income for the year** | | **(315,724)** | 27,467 |
| **Loss per share** | | | |
| – Basic and diluted (RMB) | | **(0.39)** | (0.59) |

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AT DECEMBER 31, 2024

| | NOTES | 31/12/2024 RMB'000 | 31/12/2023 RMB'000 |
|---|---|---|---|
| **Non-current assets** | | | |
| Property, plant and equipment | | **435,016** | 444,365 |
| Right-of-use assets | | **16,514** | 23,286 |
| Intangible assets | | **2,438,120** | 1,140,181 |
| Equity instruments at FVTOCI | | **11,546** | 364,148 |
| Financial assets at fair value through profit or loss ("FVTPL") | | **1,388** | – |
| Deposits and prepayments | | **92,425** | 93,385 |
| | | **2,995,009** | 2,065,365 |
| **Current assets** | | | |
| Inventories | | **45,518** | 32,473 |
| Trade and other receivables | *7* | **164,072** | 110,961 |
| Contract assets | | **–** | 8,399 |
| Bank balances and cash | *8* | **769,205** | 1,053,801 |
| | | **978,795** | 1,205,634 |
| **Current liabilities** | | | |
| Trade and other payables | *9* | **141,334** | 182,619 |
| Income tax payables | | **1,038** | 339 |
| Borrowings | *10* | **2,056** | 120,000 |
| Lease liabilities | | **6,843** | 12,326 |
| Contract liabilities | | **3,289** | – |
| Deferred income | | **441** | – |
| | | **155,001** | 315,284 |
| **Net current assets** | | **823,794** | 890,350 |
| **Total assets less current liabilities** | | **3,818,803** | 2,955,715 |
| **Capital and reserves** | | | |
| Share capital | | **58** | 48 |
| Reserves | | **3,773,559** | 2,919,920 |
| **Total equity** | | **3,773,617** | 2,919,968 |
| **Non-current liabilities** | | | |
| Lease liabilities | | **2,393** | 5,657 |
| Contract liabilities | | **28,302** | 30,090 |
| Borrowings | *10* | **14,491** | – |
| | | **45,186** | 35,747 |

# NOTES TO THE CONSOLIDATED FINANCIAL INFORMATION

## 1. GENERAL INFORMATION

The Company is a public limited company incorporated in the Cayman Islands and its shares are listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "Hong Kong Stock Exchange") effective from July 10, 2020. The addresses of the registered office and principal place of business of the Company are disclosed in the "Corporate Information" section to the annual report.

The Company (together with its subsidiaries, collectively referred to as the "Group") is a specialty biopharmaceutical platform company committed to discovering (through either in-licensing or self-development), developing and commercializing innovative and best-in-class therapies for ophthalmic patients in the People's Republic of China (the "PRC").

The consolidated financial statements are presented in Renminbi ("RMB"), which is also the functional currency of the Company.

## 2. APPLICATION OF NEW AND AMENDMENTS TO INTERNATIONAL FINANCIAL REPORTING STANDARDS ("IFRSs")

**Amendments to IFRSs that are mandatorily effective for the current year**

In the current year, the Group has applied the following amendments to IFRSs issued by the International Accounting Standards Board ("IASB") for the first time, which are mandatorily effective for the Group's annual period beginning on January 1, 2024 for the preparation of the consolidated financial statements:

| | |
|---|---|
| Amendments to IFRS 16 | Lease Liability in a Sale and Leaseback |
| Amendments to IAS 1 | Classification of Liabilities as Current or Non-current |
| Amendments to IAS 1 | Non-current Liabilities with Covenants |
| Amendments to IAS 7 and IFRS 7 | Supplier Finance Arrangements |

Except for the amendments to IFRSs mentioned below, the application of the amendments to IFRSs in the current year has had no material impact on the Group's financial positions and performance for the current and prior years and/or on the disclosures set out in these consolidated financial statements.

***Impacts on application of Amendments to IAS 1 Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2020) (the "2020 Amendments") and Amendments to IAS 1 Non-current Liabilities with Covenants (the "2022 Amendments")***

The Group has applied the amendments for the first time in the current year.

The 2020 Amendments provide clarification and additional guidance on the assessment of right to defer settlement for at least twelve months from reporting date for classification of liabilities as current or non-current, which:

- specify that the classification of liabilities as current or non-current should be based on rights that are in existence at the end of the reporting period. Specifically, the classification should not be affected by management intentions or expectations to settle the liability within 12 months.

- clarify that the settlement of a liability can be a transfer of cash, goods or services, or the entity's own equity instruments to the counterparty. If a liability has terms that could, at the option of the counterparty, result in its settlement by the transfer of the entity's own equity instruments, these terms do not affect its classification as current or non-current only if the entity recognises the option separately as an equity instrument applying IAS 32 *Financial Instruments: Presentation*.

***Impacts on application of Amendments to IAS 1 Classification of Liabilities as Current or Non-current and related amendments to Hong Kong Interpretation 5 (2020) (the "2020 Amendments") and Amendments to IAS 1 Non-current Liabilities with Covenants (the "2022 Amendments") (continued)***

For rights to defer settlement for at least twelve months from reporting date which are conditional on the compliance with covenants, the 2022 Amendments specifically clarify that only covenants that an entity is required to comply with on or before the end of the reporting period affect the entity's right to defer settlement of a liability for at least twelve months after the reporting date, even if compliance with the covenant is assessed only after the reporting date. The 2022 Amendments also specify that covenants with which an entity must comply after the reporting date (i.e. future covenants) do not affect the classification of a liability as current or non-current at the reporting date. However, if the entity's right to defer settlement of a liability is subject to the entity complying with covenants within twelve months after the reporting period, an entity discloses information that enables users of financial statements to understand the risk of the liabilities becoming repayable within twelve months after the reporting period. This would include information about the covenants, the carrying amount of related liabilities and facts and circumstances, if any, that indicate that the entity may have difficulties complying with the covenants.

In accordance with the transition provision, the Group has applied the new accounting policy to the classification of liability as current or non-current retrospectively. The application of the amendments in the current year had no material impact on the consolidated financial statements.

**New and Amendments to IFRSs in issue but not yet effective**

The Group has not early applied the following new and amendments to IFRSs that have been issued but are not yet effective:

| | |
|---|---|
| Amendments to IFRS 9 and IFRS 7 | Amendments to the Classification and Measurement of Financial Instruments[3] |
| Amendments to IFRS 9 and IFRS 7 | Contracts Referencing Nature – dependent Electricity[3] |
| Amendments to IFRS 10 and IAS 28 | Sale or Contribution of Assets between an Investor and its Associate or Joint Venture[1] |
| Amendments to IFRS Accounting Standards | Annual Improvements to IFRS Accounting Standards – Volume 11[3] |
| Amendments to IAS 21 | Lack of Exchangeability[2] |
| IFRS 18 | Presentation and Disclosure in Financial Statements[4] |

[1] Effective for annual periods beginning on or after a date to be determined.

[2] Effective for annual periods beginning on or after January 1, 2025.

[3] Effective for annual periods beginning on or after January 1, 2026.

[4] Effective for annual periods beginning on or after January 1, 2027.

Except for the new and amendments to IFRSs mentioned below, the directors of the Company anticipate that the application of all other amendments to IFRSs will have no material impact on the consolidated financial statements in the foreseeable future.

***Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments***

The amendments to IFRS 9 clarify the recognition and derecognition for financial asset and financial liability and add an exception which permits an entity to deem a financial liability to be discharged before the settlement date if it is settled in cash using an electronic payment system if, and only if certain conditions are met.

***Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments (continued)***

The amendments also provide guidance on the assessment of whether the contractual cash flows of a financial asset are consistent with a basic lending arrangement. The amendments specify that an entity should focus on what an entity is being compensated for rather than the compensation amount. Contractual cash flows are inconsistent with a basic lending arrangement if they are indexed to a variable that is not a basic lending risk or cost. The amendments state that, in some cases, a contingent feature may give rise to contractual cash flows that are consistent with a basic lending arrangement both before and after the change in contractual cash flows, but the nature of the contingent event itself does not relate directly to changes in basic lending risks and costs. Furthermore, the description of the term "non-recourse" is enhanced and the characteristics of "contractually linked instruments" are clarified in the amendments. The disclosure requirements in IFRS 7 in respect of investments in equity instruments designated at fair value through other comprehensive income are amended. In particular, entities are required to disclose the fair value gain or loss presented in other comprehensive income during the period, showing separately those related to investments derecognised during the reporting period and those related to investments held at the end of the reporting period. An entity is also required to disclose any transfers of the cumulative gain or loss within equity related to the investments derecognised during the reporting period. In addition, the amendments introduce the requirements of qualitative and quantitative disclosure of contractual terms that could affect the contractual cash flow based on a contingent event not directly relating to basic lending risks and cost.

The amendments are effective for annual reporting periods beginning on or after 1 January 2026, with early application permitted. The application of the amendments is not expected to have significant impact on the financial position and performance of the Group.

***IFRS 18 Presentation and Disclosure in Financial Statements***

IFRS 18 *Presentation and Disclosure in Financial Statements*, which sets out requirements on presentation and disclosures in financial statements, will replace IAS 1 *Presentation of Financial Statements*. This new IFRS Accounting Standard, while carrying forward many of the requirements in IAS 1, introduces new requirements to present specified categories and defined subtotals in the statement of profit or loss; provide disclosures on management-defined performance measures in the notes to the financial statements and improve aggregation and disaggregation of information to be disclosed in the financial statements. In addition, some IAS 1 paragraphs have been moved to IAS 8 and IFRS 7. Minor amendments to IAS 7 *Statement of Cash Flows* and IAS 33 *Earnings per Share* are also made.

IFRS 18, and amendments to other standards, will be effective for annual periods beginning on or after 1 January 2027, with early application permitted. The application of the new standard is expected to affect the presentation of the statement of profit or loss and disclosures in the future financial statements. The Group is in the process of assessing the detailed impact of IFRS 18 on the Group's consolidated financial statements.

## 3. REVENUE AND SEGMENT INFORMATION

### (i) Disaggregation of revenue from contracts with customers

The following is an analysis of the Group's revenue:

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| **Timing of revenue recognition** | | |
| *At a point in time* | | |
| Sales of ophthalmic products | **384,345** | 204,695 |
| Pharmaceutical products promotion services | **15,706** | 38,347 |
| Sales-based royalty income | **7,175** | 3,054 |
| Contract development and manufacturing ("CDMO") services | **10,081** | 271 |
| | **417,307** | 246,367 |

**(ii) Performance obligations for contracts with customers**

***Sales of ophthalmic products***

For the sale of ophthalmic products, revenue is recognised when control of the goods has transferred, being when the goods have been delivered to the customer's specific location, i.e. when the products are delivered and titles have passed to customers upon receipt by customer. Following delivery, the customer has the primary responsibility when selling the goods and bears the risk of obsolescence and loss in relation to the goods. A receivable is recognised by the Group when the goods are delivered to customers as this represents the point in time at which the right to consideration becomes unconditional, as only the passage of time is required before payment is due. The normal credit term is 30 to 90 days upon delivery. Under the Group's standard contract terms, customers can only return or request refund if the goods delivered do not meet required quality standards. Therefore, the probability of significant reversal in revenue in relation to sales return in the future is remote.

***Pharmaceutical products promotion services***

For pharmaceutical products promotion services, the Group is an agent under the pharmaceutical products promotion services contracts as its performance obligation is mainly to arrange for sales and/or delivery of pharmaceutical products supplied by another parties. In this regard, the Group does not control the products provided by another party before those goods sold and delivered to the end customers. The contracts of pharmaceutical products promotion services may contain variable consideration on sales basis. Accordingly, revenue is recognised at a point in time when the Group satisfies its obligation to arrange for sales and/or delivery of pharmaceutical products pursuant to the service contracts. The normal credit term is 30 to 45 days. Payment for services is not due from the customer until the Group's customer has received settlements for its sales or accepted the compliance report for promotion activities, as appropriate, and therefore a contract asset is recognised at the point of time in which the services are performed. No further obligation is borne by the Group after the promotion services have been completed.

***Sales-based royalty income***

The contracts in relation to royalty income contain variable consideration. The Group grants its license right to a customer for product sales in exchange for sales-based royalty income. The income is based on the profit margin of each sale and is recognised at a point of time upon the customer completes its sales. Such income is settled by month with the normal credit period of 60 days.

***CDMO services***

The Group starts to earn revenues by providing CDMO services to its customer through fee-for-service ("FFS") contracts. Under FFS method, the contracts usually have multiple deliverable units, which are generally in the form of reports, samples and/or products, each with individual selling price specified within the contract. The Group identifies each deliverable unit as a separate performance obligation and recognizes FFS revenue of contractual elements at the point in time upon the units delivered.

**(iii) Transaction price allocated to the remaining performance obligation for contracts with customers**

All of the Group's remaining performance obligations for contracts with customers are for periods of one year or less. As permitted under IFRS 15, the transaction price allocated to these unsatisfied contracts is not disclosed.

**Segment information**

The Group's chief operating decision maker ("CODM"), being the executive directors of the Company, regularly reviews revenue by products; however, no other discrete information was provided. In addition, the CODM reviewed the consolidated results when making decisions about allocating resources and assessing performance as a whole. Hence, no further segment information other than entity wide information was presented.

No analysis of the Group's assets and liabilities by operating segments is disclosed as it is not regularly provided to the CODM for review.

All revenue from external customers is attributed to the Group and RMB413,759,000 (2023: RMB243,689,000) of revenue was derived from the PRC. All non-current assets of the Group are located in the PRC.

**Information about major customers**

Revenue from customers contributing over 10% of the total sales of the Group are as follows:

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Customer A (note ii) | **305,002** | 140,655 |
| Customer B (note i) | **–** | 35,194 |
| Customer C (note ii) | **–** | 29,599 |

Notes:

(i) Revenue on pharmaceutical product promotion services

(ii) Revenue on sales of ophthalmic products

## 4. OTHER INCOME

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Bank interest income | **22,219** | 21,920 |
| Compensation from Alcon (note i) | **21,684** | – |
| Government grant income (note ii) | **1,703** | 458 |
| Others | **1,132** | 825 |
| | **46,738** | 23,203 |

Notes:

(i) The amount represents the compensation from Alcon for potential higher than expected stock in the trade of one commercial product in relation to the original distributor of Alcon continuing to sell the inventory after Ocumension acquired the commercialization right of the commercial product.

(ii) Government grants include unconditional subsidies from the PRC government which are specifically for research and development activities, employment support and training, innovation and development support.

## 5. OTHER GAINS AND LOSSES

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Net foreign exchange gain | **1,919** | 1,096 |
| Gain from changes in fair value of other financial assets | **450** | 1,155 |
| Impairment loss reversed on long-lived assets | **–** | 3,179 |
| Fair value loss of financial assets at FVTPL | **(160)** | – |
| Other losses related to Nicox (note) | **(612)** | – |
| Others | **(167)** | – |
| | **1,430** | 5,430 |

Note:

During current year, the Company recognised loss of RMB612,000 in other gains and loss resulting from the acquisition on the shares of Nicox, which is the difference between the acquisition date market quoted prices and the agreed subscription prices of shares.

## 6. INCOME TAX EXPENSE

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Current tax – Hong Kong | **420** | 232 |
| Current tax – the PRC | **597** | 107 |
| Over provision for prior years | **–** | (32) |
| | **1,017** | 307 |

The Company was incorporated in the Cayman Islands and is exempted from income tax.

Ocumension (Hong Kong) Limited ("Ocumension Hong Kong") generated royalty income during the years ended December 31, 2024 and 2023. Under the two-tiered profits tax rates regime of Hong Kong Profits Tax, the qualifying group entity is calculated at 8.25% on the first HK$2 million of the estimated assessable profits and at 16.5% on the estimated assessable profits above HK$2 million.

Pursuant to the Enterprise Income Tax Law and Implementation Regulations of the Law of the PRC, the applicable tax rate of the PRC subsidiaries is 25% for both years.

## 7. TRADE AND OTHER RECEIVABLES

The Group allows an average credit period of 30 to 90 days to its trade customers, and the credit terms of certain trade customers are based on the timing of their actual sales. The following is an aged analysis of trade receivable, presented based on invoice date:

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| 0-90 days | **125,470** | 80,142 |
| 91-180 days | **218** | – |
| Over 180 days | **–** | 9,206 |
| | **125,688** | 89,348 |

As at December 31, 2024, included in the Group's trade receivables balance are debtors with aggregate carrying amount of RMB218,000 (2023: RMB9,206,000) which are past due, of which none were overdue by more than 90 days as of the reporting date (2023: RMB9,206,000). The Group maintains adequate credit policy to access the credit quality of the customers and closely monitored to minimise any credit risk associated with the trade debtors. The Group's customers have good repayment history during the current year, and strong financial capacity as they are the subsidiaries of large listed corporate in the PRC.

## 8. BANK BALANCES AND CASH

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Cash at bank | **255,118** | 547,139 |
| Term deposits | **514,087** | 506,662 |
| | **769,205** | 1,053,801 |
| Analysed as: | | |
| Cash and cash equivalents | 729,205 | 842,839 |
| Term deposits with maturity date between three months to one year (note a) | 40,000 | 206,662 |
| Pledged bank deposits (note b) | – | 4,300 |
| | 769,205 | 1,053,801 |

Notes:

(a) The term deposits are under the Group's rights of early redemption at its principal before the maturity date. In the event of early withdrawal prior to maturity, a prevailing current account interest rate would be offered instead of the term deposits interest rate without any penalty.

(b) Pledged bank deposits represented deposits pledged to a bank to secure the letter of credit granted to the Group and classified as current asset.

## 9. TRADE AND OTHER PAYABLES

The average credit period purchases of goods/services of the Group is within 30 days. Ageing analysis of the Group's trade payables based on the invoice dates at the end of the reporting period is as follows:

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| 0 – 30 days | **30,888** | 24,285 |
| 31 – 60 days | **2,798** | 755 |
| More than 60 days | **733** | 152 |
| | **34,419** | 25,192 |

## 10. BORROWINGS

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| Guaranteed bank loans | **16,547** | 120,000 |

The carrying amounts of the above borrowings are analysed based on contractual repayment date as follows:

| | **2024** | 2023 |
|---|---|---|
| | ***RMB'000*** | *RMB'000* |
| The carrying amounts of the borrowings are repayable: | | |
| Within one year | **2,056** | 120,000 |
| Within a period of more than one year but not exceeding two years | **4,112** | – |
| Within a period of more than two years but not exceeding five years | **10,379** | – |
| | **16,547** | 120,000 |
| Less: Amount due for settlement with 12 months shown under current liabilities | **(2,056)** | (120,000) |
| Amount due for settlement after 12 months shown under non-current liabilities | **14,491** | – |

Subsidiaries of the Group entered into loan agreements with banks. The interest rates are one-year's Loan Prime Rate ("LPR") minus 0.35% (2023:3.0%~3.1%). The borrowings are guaranteed by the group entities.

## 11. DIVIDENDS

No dividend was paid or declared during the year ended December 31, 2024, nor has any dividend been proposed since the end of the reporting period (2023: nil).

## OTHER INFORMATION

### Compliance with the Corporate Governance Code

The Company is committed to maintaining a high standard of corporate governance to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has adopted the code provisions of the CG Code as set out in Appendix C1 to the Listing Rules as its own code of corporate governance. On October 21, 2024, Ms. Yumeng WANG resigned as a non-executive Director as she decided to devote more time to her other engagements. Following her resignation, the Company temporarily failed to have a board with different genders required by Rule 13.92 of the Listing Rules. On January 16, 2025, Dr. Qin XIE was appointed as a non-executive Director, making the Company achieve the gender diversity for members of the Board and in full compliance with the requirements under Rule 13.92 of the Listing Rules.

Save for the deviation to the Board diversity for less than three months as set forth above, the Board is of the view that the Company has complied with all applicable code provisions of the CG Code during the Reporting Period. The Board will review the corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

### Compliance with the Model Code for Securities Transactions

The Company has adopted the Written Guidelines on no less exacting terms than the Model Code as its own code of conduct regarding securities transactions by the Directors.

Having made specific enquiries of all Directors, all of them have confirmed that they have complied with the Model Code and the Written Guidelines during the Reporting Period. No incident of non-compliance of the Written Guidelines by the employees who are likely to be in possession of inside information of the Company was noted by the Company.

### Use of Proceeds from Listing and Placing

#### *Use of Proceeds from the Listing*

The Company was listed on the Main Board of the Stock Exchange on July 10, 2020. The total net proceeds raised from the issue of new Shares by the Company in its Listing and the full exercise of over-allotment option (after deducting the underwriting fees and related Listing expenses) amounted to approximately HK$1,646.41 million. The intended use of the net proceeds and the change in the intended use of the net proceeds were set out in the Prospectus and announcement of the Company dated September 11, 2020, respectively. As of December 31, 2024, such net proceeds from Listing were utilized as follows in accordance with the intended uses:

| Use of proceeds from Listing | Amount of net proceeds for planned applications *(HK$ million)* | Percentage of total net proceed *(%)* | Unutilized net proceeds as of December 31, 2023 *(HK$ million)* | Utilized net proceeds during the Reporting Period *(HK$ million)* | Utilized net proceeds as of December 31, 2024 *(HK$ million)* | Unutilized net proceeds as of December 31, 2024 *(HK$ million)* | Expected time frame for unutilized amount |
|---|---|---|---|---|---|---|---|
| **For the Core Product** | | | | | | | |
| 1. For funding the costs and expenses in connection with R&D personnel as well as the continuing R&D activities of OT-401 | 197.57 | 12.00% | 106.22 | 6.96 | 98.30 | 99.27 | by the end of 2025 |
| 2. For milestone payments of OT-401 | 49.39 | 3.00% | 15.49 | – | 33.90 | 15.49 | –[(1)] |
| 3. For the commercialization of OT-401 | 246.96 | 15.00% | 49.95 | 49.95 | 246.96 | – | – |
| **For the other drug candidates, including OT-101, OT-301, OT-1001, OT-502, OT-202, OT-503 and OT-701** | | | | | | | |
| 1. For the continuing R&D activities of other drug candidates, including OT-101, OT-301, OT-1001, OT-502, OT-202, OT-503 and OT-701 | 562.42 | 34.16% | – | – | 562.42 | – | – |
| 2. For milestone payments of our other in-licensed drug candidates | 96.15 | 5.84% | 22.47 | – | 73.68 | 22.47 | by the end of 2027[(2)] |
| 3. For the further expansion of our sales and marketing team | 164.64 | 10.00% | – | – | 164.64 | – | – |
| **For the acquisition of 100% equity interest in Suzhou Xiaxiang as disclosed in our announcement dated September 11, 2020** | **164.64** | **10.00%** | **–** | **–** | **164.64** | **–** | **–** |
| **For our working capital and other general corporate purposes** | **164.64** | **10.00%** | **–** | **–** | **164.64** | **–** | **–** |
| **Total** | **1,646.41** | **100.00%** | **194.13** | **56.91** | **1,509.18** | **137.23** | |

*Notes:* (1) The remaining balance of RMB15.49 million was due to a reduction in milestone payments agreed by the parties.

(2) Certain milestone payments have been deferred pending achievement of required project milestones.

As of December 31, 2024, all the unused net proceeds are held by the Company in short-term deposits with licensed banks or authorized financial institutions.

***Use of Proceeds from the Placing***

In January 2021, an aggregate of 28,000,000 placing Shares have been successfully placed by Morgan Stanley & Co. International plc to not less than six Independent Third Party placees at the placing price of HK$28.35 per Share. For details of the placing and subscription, please refer to the Company's announcements dated January 13, 2021 and January 22, 2021, respectively.

The net proceeds arising from the placing and subscription amounted approximately HK$781.7 million, of which the intended uses were set out in the announcement of the Company dated January 22, 2021. The placing and subscription was undertaken to strengthen the Group's financial position and for the long term funding of its business, expansion and growth plan. As of December 31, 2024, the net proceeds from the placing and subscription were utilized as follows in accordance with the intended uses:

| Use of proceeds from placing and subscription | Amount of net proceeds for planned applications *(HK$ million)* | Percentage of total net proceeds *(%)* | Unutilized net proceeds as of December 31, 2023 *(HK$ million)* | Utilized net proceeds during the Reporting Period *(HK$ million)* | Utilized net proceeds as of December 31, 2024 *(HK$ million)* | Unutilized proceeds as of December 31, 2024 *(HK$ million)* | Expected time frame for unutilized amount |
|---|---|---|---|---|---|---|---|
| **Expansion of the Company's commercial team in view of the proposed launch of its new therapies** | **234.51** | **30.00%** | **234.51** | **125.41** | **125.41** | **109.10** | **by the end of 2025** |
| **Funding of International multi-center clinical trials of the Company's therapies** | **273.60** | **35.00%** | **25.23** | **3.46** | **251.83** | **21.77** | **–(1)** |
| OT-702 (Eylea biosimilar) | 99.66 | 12.75% | – | – | 99.66 | – | – |
| OT-301 (NCX-470) | 50.03 | 6.40% | – | – | 50.03 | – | – |
| OT-101 (low-concentration atropine) | 43.78 | 5.60% | – | – | 43.78 | – | – |
| OT-1001 (Zerviate) | 30.10 | 3.85% | 22.40 | 0.63 | 8.33 | 21.77 | –(1) |
| OT-202 (TKI) | 50.03 | 6.40% | 2.83 | 2.83 | 50.03 | – | – |
| **Building and development of new manufacturing facilities and equipment of Suzhou Xiaxiang and active pharmaceutical ingredients manufacturing facilities** | **195.43** | **25.00%** | **–** | **–** | **195.43** | **–** | **–** |
| **Other general corporate purposes** | **78.17** | **10.00%** | **–** | **–** | **78.17** | **–** | **–** |
| **Total** | **781.71** | **100.00%** | **259.74** | **128.87** | **650.84** | **130.87** | |

*Note:* (1) The R&D of OT-1001 has been completed with a balance of RMB21.77 million.

As of December 31, 2024, all the unused net subscription proceeds have been deposited into the bank account(s) maintained by our Group.

## Purchase, Sale or Redemption of the Listed Securities of the Company

During the Reporting Period, the Company repurchased a total of 18,807,000 Shares for an aggregate consideration of HK$104,357,708 on the Stock Exchange before expenses. The Company canceled a total of 1,960,000 repurchased Shares (including 239,000 Shares repurchased in 2023) on May 21, 2024. The repurchase was effectuated by the Board for the enhancement of the value of our Shareholder in the long term. Details of the Share repurchase are as follows:

| | Shares repurchased | Consideration per Share | | Aggregate |
|---|---|---|---|---|
| **Month** | **No. of Shares repurchased** | **Highest price paid** *(HK$)* | **Lowest price paid** *(HK$)* | **consideration Paid** *(HK$)* |
| January 2024 | 1,721,000 | 6.61 | 5.51 | 10,227,016 |
| August 2024 | 11,679,000 | 6.60 | 5.17 | 64,694,686 |
| September 2024 | 189,000 | 5.00 | 4.53 | 915,860 |
| October 2024 | 2,440,500 | 6.81 | 5.20 | 14,587,566 |
| November 2024 | 1,687,000 | 5.81 | 5.03 | 8,976,375 |
| December 2024 | 1,090,500 | 5.34 | 4.37 | 4,956,205 |
| **Total** | **18,807,000** | | | **104,357,708** |

Save as disclosed above, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale of treasury Shares) during the Reporting Period. As of December 31, 2024, 17,086,000 Shares were repurchased and held in treasury by the Company.

## Final Dividend

The Board does not recommend the distribution of a final dividend for the year ended December 31, 2024 (2023: nil).

## Events After the Reporting Period

There was no event which has occurred after the year ended December 31, 2024 and up to the date of this announcement that would cause material impact on the Group.

## Scope of Work of Messrs. Deloitte Touche Tohmatsu

The figures in respect of the Group's consolidated statement of financial position, consolidated statement of profit or loss and other comprehensive income and the related notes thereto for the year ended December 31, 2024 as set out in this announcement have been agreed by the Group's auditor, Messrs. Deloitte Touche Tohmatsu, to the amounts set out in the audited consolidated financial statements of the Group for the year as approved by the Board on March 31, 2025. The work performed by Messrs. Deloitte Touche Tohmatsu in this respect did not constitute an assurance engagement and consequently no opinion or assurance conclusion has been expressed by Messrs. Deloitte Touche Tohmatsu on this announcement.

## Review of the Annual Results

The Audit Committee comprises three independent non-executive Directors, namely, Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG. The chairman of the Audit Committee is Mr. Ting Yuk Anthony WU. The Audit Committee has reviewed the annual results of the Group for the year ended December 31, 2024 and has recommended for the Board's approval thereof.

The Audit Committee has reviewed together with the management the accounting principles and policies adopted by the Group and the consolidated financial statements for the year ended December 31, 2024. The Audit Committee considered that the annual results are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

## AGM and Closure of the Register of Members

The Company will arrange the time of convening the AGM as soon as practicable and in accordance with the Listing Rules. A notice convening the AGM will be published and dispatched to the Shareholders in the manner required by the Listing Rules and the Articles of Association in due course. Once the date of the AGM is finalized, the Company will publish the period of closure of register of members of the Company in the notice of the AGM.

## Publication of Annual Results and Annual Report

This announcement is published on the website of the Stock Exchange (**www.hkexnews.hk**) and the Company's website (**www.ocumension.com**). The annual report of the Company for the year ended December 31, 2024 containing all the information in accordance with the requirements under the Listing Rules will be dispatched to the Shareholders and published on the respective websites of the Stock Exchange and the Company in due course.

## Appreciation

The Board would like to express its sincere gratitude to the Shareholders, management, employees, business partners and customers of the Group for their support and contribution to the Group.

| | |
|---|---|
| "2021 Share Award Scheme" | the share award scheme adopted by the Company in accordance with the scheme rules thereof on July 2, 2021 and amended from time to time, the details of which are set out in the circular of the Company dated May 24, 2024 |
| "2021 Share Option Scheme" | the share option scheme adopted by the Board in accordance with the rules thereof on July 2, 2021, approved by the Shareholders on the extraordinary general meeting of the Company held on August 31, 2021 and amended from time to time, the details of which are set out in the circular of the Company dated May 24, 2024 |
| "2024 Share Award Scheme" | the share award scheme adopted by the Company on March 21, 2024 involving its existing Shares in accordance with the scheme rules thereof, as amended from time to time |
| "AGM" | the annual general meeting of the Company in 2025 |
| "Alcon" | Alcon Inc., the global leader in eye care with complementary businesses in surgical and vision care and a stock corporation organized under the laws of Switzerland, the shares of which are listed on SIX Swiss Exchange and the New York Stock Exchange under the ticker symbol ALC |
| "Alcon Group" | Alcon and its subsidiaries (including Alcon Pharma) |
| "Alcon Pharma" | Alcon Pharmaceuticals Ltd, a company organized and existing under the laws of Switzerland and a wholly owned subsidiary of Alcon, one of our substantial Shareholders |
| "Alcon Transaction" | the acquisition of the Transferred Products and the royalty payments under the Asset Purchase Agreement, the in-licensing of the Pipeline Product and the Commercial Product and the royalty payments and sales milestone payments under the License Agreement, the issue of Share to Alcon Pharma under the Subscription Agreement and the purchase arrangements under the Manufacture and Supply Agreement |
| "Articles of Association" | the articles of association of the Company conditionally adopted on June 23, 2020 and effective on July 10, 2020, as amended from time to time |

| | |
|---|---|
| "Asset Purchase Agreement" | the asset purchase agreement entered into by and between Ocumension HK and Alcon Research, LLC on August 12, 2024 in respect of the acquisition of the Transferred Products |
| "Audit Committee" | the audit committee of the Board |
| "Board" | the board of directors of the Company |
| "CDE" | the Center for Drug Evaluation of NMPA (國家藥品監督管理局藥品審評中心), a division of the NMPA mainly responsible for review and approval of IND and NDA |
| "CG Code" | the Corporate Governance Code as set out in Appendix C1 to the Listing Rules |
| "China" or "the PRC" | the People's Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires, references in this announcement to "China" and the "PRC" does not include Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan |
| "chronic NIU-PS" | chronic non-infectious uveitis affecting the posterior segment of the eye |
| "Commercial Product" | Systane® Ultra (Lubricant eye drops) |
| "Company" | Ocumension Therapeutics (歐康維視生物), a company incorporated under the laws of the Cayman Islands with limited liability on February 27, 2018, the shares of which were listed on the Main Board of the Stock Exchange on July 10, 2020 |
| "Core Product" | has the meaning ascribed to it in Chapter 18A of the Listing Rules; for purposes of this announcement, our Core Product refers to OT-401 (YUTIQ®, 0.18mg fluocinolone intravitreal implant, trade name: Youshiying® (優施瑩®)) |
| "Director(s)" | the director(s) of our Company, including all executive directors, non-executive directors and independent non-executive directors |
| "ESOP" | the employee stock option plan adopted by our Company on May 23, 2018, as amended from time to time, the details of which are set out in the Prospectus |
| "EyePoint" | EyePoint Pharmaceuticals, Inc., a company whose shares of common stock are listed on the NASDAQ (ticker symbol: EYPT) and a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products for the treatment of eye diseases |
| "EyePoint Share(s)" | share(s) of common stock of a par value of US$0.001 per share of EyePoint |

| | |
|---|---|
| "FDA" | the United States Food and Drug Administration |
| "FVTOCI" | fair value through other comprehensive income |
| "Greater China" | the PRC, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan |
| "Group" or "Ocumension" | the Company and its subsidiaries |
| "Grade III hospital(s)" | the top-level hospital(s) in China, as hospitals in China are divided into three classes by National Health Commission of the PRC (中華人民共和國國家衛生健康委員會), among which, Class III hospitals are at the highest level, typically having more than 500 beds, providing high-level specialist medical and healthcare services to several regions and performing advanced teaching and research tasks |
| "HK$" | Hong Kong dollars, the lawful currency of Hong Kong |
| "Hong Kong" | the Hong Kong Special Administrative Region of the PRC |
| "IFRS" | International Financial Reporting Standards |
| "IND" | investigational new drug, the application for which is the first step in the drug review process by regulatory authorities to decide whether to permit clinical trials. Also known as CTA in China |
| "Independent Third Party(ies)" | party or parties that, to the best of our Directors' knowledge, information and belief, having made all reasonable inquiries, is or are not a connected person or connected persons of the Company |
| "License Agreement" | the license agreement entered into between Ocumension HK and Alcon Pharma on August 12, 2024 in respect of the exclusive license to develop, manufacture and commercialize the Pipeline Product for dry eye uses and to commercialize the Commercial Product obtained by Ocumension HK from Alcon Pharma in the PRC |
| "Listing" | the listing of our Shares on the Main Board of the Stock Exchange |
| "Listing Rules" | the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time |
| "Manufacture and Supply Agreement" | the manufacture and supply agreement entered into by and between Ocumension HK and Alcon Pharma on August 12, 2024 in respect of, pursuant to which, Ocumension HK agreed to purchase from Alcon Pharma relevant products during the periods agreed by the parties |

| | |
|---|---|
| "Model Code" | the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules |
| "NASDAQ" | The Nasdaq Stock Market LLC |
| "NDA" | new drug application, an application through which the drug sponsor formally proposes that the relevant regulatory authority approve a new drug for sales and marketing |
| "Nicox" | Nicox S.A., a corporation incorporated under the laws of France on February 15, 1996, one of our licensing partners whose shares are listed on the Euronext exchange (ticker symbol: COX) |
| "NMPA" | National Medical Products Administration (國家藥品監督管理局), formerly the China Food and Drug Administration (國家食品藥品監督管理局), or CFDA |
| "NHSA" | National Healthcare Security Administration (國家醫療保障局) of the PRC |
| "NRDL" | National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance《國家基本醫療保險、工傷保險和生育保險藥品目錄》 |
| "Ocumension HK" | Ocumension (Hong Kong) Limited, a company incorporated under the laws of Hong Kong and a wholly owned subsidiary of the Company |
| "Pipeline Product" | dry eye product candidate known as AR-15512 |
| "Prospectus" | the prospectus issued by the Company dated June 29, 2020 |
| "RMB" | Renminbi Yuan, the lawful currency of China |
| "Reporting Period" | the one-year period from January 1, 2024 to December 31, 2024 |
| "RSU Scheme" | the restricted share unit scheme adopted by the Company on April 28, 2020, the details of which are set out in the Prospectus |
| "R&D" | research and development |
| "Share(s)" | ordinary shares in the share capital of our Company of US$0.00001 each |
| "Shareholder(s)" | holder(s) of Shares |
| "Stock Exchange" | The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited |

| | |
|---|---|
| "Subscription Agreement" | the subscription agreement entered into by and between the Company and Alcon Pharma on August 12, 2024, pursuant to which the Company agreed to conduct the Alcon Consideration Issue |
| "Suzhou Xiaxiang" | Suzhou Xiaxiang Biomedicine Co., Ltd. (蘇州夏翔生物醫藥有限公司), a limited liability company established in the PRC on October 18, 2019 |
| "Transferred Products" | six products under the Asset Purchase Agreement, namely Tears Naturale® Forte (Lubricant eye drops), Tears Naturale® II (Lubricant eye drops), Bion® Tears (Lubricant eye drops), Alcaine® (Topical local anesthetic eye drops), Fluorescite® (Diagnostic agent for IV administration) and Cyclogyl® (Muscarinic antagonist eye drops), collectively |
| "U.S." or "United States" | the United States of America, its territories, its possessions and all areas subject to its jurisdiction |
| "US$" | United States dollars, the lawful currency of the United States |
| "wAMD" | wet age-related macular degeneration |
| "Written Guidelines" | the Guidelines for Securities Transactions by Directors adopted by the Company |
| "%" | Per cent |

By order of the Board
**Ocumension Therapeutics**
**Dr. Lian Yong CHEN**
*Chairman and Non-executive Director*

Hong Kong, March 31, 2025

*As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Mr. Ting Yuk Anthony WU, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.*